<DOC>
	<DOCNO>NCT01090921</DOCNO>
	<brief_summary>This research study see new drug call bortezomib useful treat multiple myeloma people newly diagnose , yet receive treatment disease . VELCADE® ( bortezomib ) Injection drug development Millennium Pharmaceuticals , Inc .</brief_summary>
	<brief_title>Safety Efficacy Study Single Weekly Bortezomib Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>This study multi-site study enroll 50 patient multiple myeloma prior treatment . Prior start treatment individual evaluate determine eligible participate study . There certain prestudy test require : physical exam , blood test , ECG , chest x-ray , skeletal survey , bone marrow aspirate biopsy confirm diagnosis multiple myeloma determine baseline health status . Before begin treatment cycle end study , patient protein study ( include blood urine ) see respond treatment . Before weekly treatment cycle patient also blood test red white blood cell platelet , blood chemistry test electrolytes , kidney liver function , calcium blood sugar . Patients may receive 6 cycle treatment . At end study , individual respond treatment see every two month check disease progression .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Diagnosis multiple myeloma base standard criterion . 2 . Measurable disease , define monoclonal immunoglobulin spike serum electrophoresis &gt; 1Gm/dL and/or urine monoclonal immunoglobulin spike &gt; 200mg/24 hour . 3 . Nonsecretors must measurable protein Freelite measurable disease plasmacytoma eligible . 4 . Patient must previously treat chemotherapy . Prior treatment hypercalcemia corticosteroid , bisphosphonates disqualify patient . 5 . Patient must ineligible autologous stem cell transplant due one follow reason : Age &gt; 65 Impaired renal function ( creatinine≥2.0 mg/dL ) Impaired pulmonary function ( DLCO≤50 % ) Poor performance status ( KPS≤80 ) Other prohibitive comorbid disorder 5b . Patients≥60 decline autologous stem cell transplant eligible study . 5c . Patients eligible wish postpone autologous stem cell transplant eligible study . 6 . Karnofsky performance status &gt; 50 7 . Patients treat local radiotherapy without brief exposure steroid eligible . Patients require concurrent radiotherapy entry protocol defer radiotherapy complete , follow four week wash period Spot RT ≤3 vertebra acceptable prior entry . 8 . Meets follow pretreatment laboratory criterion Baseline ( Within 14 day prior study drug administration ) : 1 . Platelet count &gt; 50x10^9/L , bone marrow extensively infiltrate , &gt; 30x10^9/L 2 . Hemoglobin &gt; 8.0G/dL 3 . Absolute neutrophil count &gt; 1.0x10^9/L , bone marrow extensively infiltrate , &gt; 0.5x10^9/L 9 . Meets follow pretreatment laboratory criterion liver function test screen visit conduct within 14 day registration 1 . AST ( SGOT ) : &lt; 3 time upper limit institutional laboratory normal 2 . ALT ( SGPT ) : &lt; 3 time upper limit institutional laboratory normal 3 . Total bilirubin : &lt; 2 time upper limit institutional laboratory normal , unless clearly related disease 10 . Women childbearing potential practicing adequate form contraception , judge investigator ( i.e . birth control pill , double barrier method , abstinence , etc . ) surgically sterile 12 month postmenopausal . Male subject agrees use acceptable method contraception duration study . 11 . Age 18 year old 12 . Has give voluntary write informed consent . 1 . POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ) 2 . Plasma cell leukemia 3 . Impaired kidney function require dialysis , patient hemodialysis exclude 4 . Receiving steroid &gt; equivalent 10mg prednisone daily medical condition , e.g. , asthma , systemic lupus erythematosis , rheumatoid arthritis 5 . Infection control antibiotic 6 . HIV infection . Patients provide consent HIV test accord institution 's standard practice 7 . Known active hepatitis B C 8 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( Appendix D ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities 9 . Second malignancy require concurrent treatment 10 . Other serious medical psychiatric illness could potentially interfere completion treatment accord protocol 11 . Positive pregnancy test woman childbearing potential 12 . Patient hypersensitivity boron mannitol . 13 . Patient ≥Grade 2 peripheral neuropathy within 14 day enrollment . 14 . Patient receive investigational drug 14 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Newly diagnose</keyword>
	<keyword>Newly diagnose Multiple Myeloma</keyword>
</DOC>